NUVECTIS PHARMA INC · Data as of 2026-09-08
Summer 2026
Mr. Bentsur concluded, "We are excited for what's ahead in 2026 and expect a preliminary data readout from the NXP900 Phase 1b study in the summer. We continue to operate with financial discipline and remain focused on achieving key clinical development milestones in our NXP900 program in 2026 and beyond."Source filing
Late 2026
Non-small cell lung cancer (NSCLC): the clinical trial evaluating the combination of NXP900 plus osimertinib (Tagrisso™) in patients with NSCLC EGFR+ who initially responded to, and later progressed on, osimertinib, is ongoing, and we expect to provide an update by the end of this year.Source filing
4Q2026
U.S. regulatory efforts underway; a pre-investigation new drug ("IND") meeting with the Food and Drug Administration ("FDA") followed by IND submission expected in 4Q2026.Source filing
4Q2026
U.S. regulatory efforts underway; IND submission expected in 4Q2026.Source filing
Oct 23–Oct 27
Oral presentation of additional clinical data generated by Haisco will be presented at the upcoming European Society for Medical Oncology (ESMO) conference (Madrid, Spain, October 23–27, 2026).Source filing